You are here

ASH 2007- New Therapeutic Options in CML and What They Mean for Patients:

New Therapeutic Options in CML and What They Mean for Patients: An Expert Interview With Dr. Jorge Cortes

Jorge Cortes
01/28/2008

Jorge Cortes, MD

Data from a number of interesting studies on the treatment of patients with chronic myelogenous leukemia (CML) were reported at the American Society of Hematology (ASH) 48th Annual Meeting, held in Atlanta, Georgia, in December 2007. Among the important information presented was an update of the IRIS trial, which compared interferon plus cytarabine with imatinib in patients with newly diagnosed CML and now 6 years of follow-up, as well as preliminary data from trials of dasatinib and nilotinib in the front-line setting in patients with CML. At the ASH meeting, Medscape contributor Sally Church, PhD, had the opportunity to review data from these and other important CML studies with Jorge Cortes, MD, Professor of Medicine and Deputy Chair of the Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston.

....more